Long-term follow-up of neointimal coverage of sirolimus-eluting stents - Evaluation with optical coherence tomography

Circulation Journal

Volumn 73, Issue 12, 2009, Pages 2300-2307

  Ishigami, Ken Ichi ^a   Uemura, Shiro ^a   Morikawa, Yoshinobu ^a   Soeda, Tsunenari ^a   Okayama, Satoshi ^a   Nishida, Taku ^a   Takemoto, Yasuhiro ^a   Onoue, Kenji ^a   Somekawa, Satoshi ^a   Takeda, Yukiji ^a   Kawata, Hiroyuki ^a   Horii, Manabu ^a   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiplatelet therapy; Drug eluting stents; Optical coherence tomography; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; LIPID; RAPAMYCIN; TICLOPIDINE;

ARTERY INTIMA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PREDICTOR VARIABLE; SMOKING; STENT THROMBOSIS; THROMBOSIS PREVENTION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 73349096901     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-1116     Document Type: Article

References (38)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents vs standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
3. Takano M, Mizuno K. Late coronary thrombosis in a sirolimuseluting stent due to the lack of neointimal coverage. Eur Heart J 2006; 27: 1133.
4. Karrillon GJ, Morice MC, Benveniste E, Bunouf P, Aubry P, Cattan S, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 1996; 94: 1519-1527.
5. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al; e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-1441.
6. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113: 2803-2809.
7. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drugeluting stent implantation. JAMA 2007; 297: 159-168.
8. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.
9. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-1971.
10. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 2006; 48: 2584-2591.
11. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008; 117: 261-295.
12. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the Sirius trial. J Am Coll Cardiol 2004; 43: 1959-1963.
13. Kataiwa H, Tanaka A, Kitabata H, Imanishi T, Akasaka T. Safety and usefulness of non-occlusion image acquisition technique for optical coherence tomography. Circ J 2008; 72: 1536-1537.
14. Tanigawa J, Barlis P, Di Mario C. Heavily calcified coronary lesions preclude strut apposition despite high pressure balloon dilatation and rotational atherectomy: In-vivo demonstration with optical coherence tomography. Circ J 2008; 72: 157-160.
15. Kume T, Akasaka T, Kawamoto T, Watanabe N, Toyota E, Sukmawan R, et al. Visualization of neointima formation by optical coherence tomography. Int Heart J 2005; 46: 1133-1136.
16. Bouma BE, Tearney GJ. Power-efficient nonreciprocal interferometer and linear-scanning fiber-optic catheter for optical coherence tomography. Opt Lett 1999; 24: 531-533.
17. Kume T, Akasaka T, Kawamoto T, Watanabe N, Toyota E, Neishi Y, et al. Assessment of coronary arterial plaque by optical coherence tomography. Am J Cardiol 2006; 97: 1172-1175.
18. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 34: 1773-1780.
19. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial. Circulation 2005; 111: 1040-1044.
20. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
21. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372.
22. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting vs bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
23. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
24. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-967.
25. Takano M, Yamamoto M, Imai S, Murakami D, Seimiya K, Ohba T, et al. Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: Do uncovered struts persist? J Am Coll Cardiol 2008; 51: 968-969.
26. Takano M, Xie Y, Murakami D, Inami S, Yamamoto M, Ohba T, et al. Various optical coherence tomographic findings in restenotic lesions after sirolimus-eluting stent implantation. Int J Cardiol 2009; 134: 263-265.
27. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007; 115: 813-818.
28. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183-188.
29. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, et al. Assessment of culprit lesion morphology in acute myocardial infarction: Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007; 50: 933-939.
30. Diaz-Sandoval LJ, Bouma BE, Tearney GJ, Jang IK. Optical coherence tomography as a tool for percutanous coronary interventions. Cathet Cardiovasc Interv 2005; 65: 492-496.
31. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999; 10: 499-506.
32. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, Lin-Shiau SY, et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol 2005; 25: 539-545.
33. Varma S, Lal BK, Zheng R, Breslin JW, Saito S, Pappas PJ, et al. Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol 2005; 289: 1744-1751.
34. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 2007; 71: 220-225.
35. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342.
36. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-1932.
37. Pinto Slottow TL, Steinberg DH, Roy PK, Buch AN, Okabe T, Xue Z, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 2008; 102: 298-303.
38. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.